MCID: BLT006
MIFTS: 48

Bilateral Breast Cancer

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bilateral Breast Cancer

MalaCards integrated aliases for Bilateral Breast Cancer:

Name: Bilateral Breast Cancer 11 53 5 14 71
Bilateral Breast Carcinoma 11 5

Classifications:



External Ids:

Disease Ontology 11 DOID:6741
NCIt 49 C8287
UMLS 71 C0281267

Summaries for Bilateral Breast Cancer

Disease Ontology: 11 A breast carcinoma that is characterized by an individual having breast cancer in both breasts, either simultaneously or at different times.

MalaCards based summary: Bilateral Breast Cancer, also known as bilateral breast carcinoma, is related to breast-ovarian cancer, familial 2 and telangiectasis. An important gene associated with Bilateral Breast Cancer is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Adenosine and Tucatinib have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and prostate, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Decreased viability

Related Diseases for Bilateral Breast Cancer

Diseases related to Bilateral Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 412)
# Related Disease Score Top Affiliating Genes
1 breast-ovarian cancer, familial 2 30.6 BRCA2 BRCA1
2 telangiectasis 30.4 TP53 CHEK2 ATM
3 gynecomastia 30.4 PGR ESR1 ERBB2
4 hereditary breast cancer 30.3 PALB2 CHEK2 CDH1 BRCA2 BRCA1
5 breast-ovarian cancer, familial 1 30.3 RAD51C PALB2 BRCA2 BRCA1
6 ataxia-telangiectasia 30.1 TP53 RAD51 CHEK2 BRCA2 BRCA1 ATM
7 neurofibromatosis, type i 30.1 TP53 MLH1 CDKN2A BRCA2
8 breast mucinous carcinoma 30.1 PGR ERBB2
9 breast squamous cell carcinoma 30.0 PGR ESR1 ERBB2
10 cervical adenocarcinoma 30.0 TP53 PGR ESR1 CDKN2A
11 mammary paget's disease 30.0 PGR ESR1 ERBB2
12 ovarian cancer 1 29.9 RAD51C PALB2 BRCA2 BRCA1
13 ovarian carcinosarcoma 29.9 TP53 ERBB2 BRCA2 BRCA1
14 tubular adenocarcinoma 29.8 PGR ESR1 ERBB2 CDH1
15 carcinosarcoma 29.8 TP53 PGR ERBB2 CDKN2A CDH1
16 mucinous adenocarcinoma 29.8 TP53 MLH1 ERBB2 CDKN2A
17 esophagus adenocarcinoma 29.8 TP53 ERBB2 CDKN2A CDH1
18 osteogenic sarcoma 29.8 TP53 ESR1 CHEK2 CDKN2A
19 breast disease 29.7 TP53 PGR FHIT ESR1 ERBB2 BRCA2
20 breast metaplastic carcinoma 29.7 TP53 PGR ESR1 ERBB2
21 ductal carcinoma in situ 29.7 TP53 PGR ESR1 ERBB2 CDKN2A CDH1
22 gastrointestinal stromal tumor 29.6 TP53 ESR1 ERBB2 CDKN2A
23 endometrial adenocarcinoma 29.6 TP53 PGR MLH1 ESR1 CDKN2A
24 comedo carcinoma 29.6 TP53 PGR ESR1 ERBB2 BRCA2
25 head and neck cancer 29.6 TP53 ERBB2 CDKN2A CDH1
26 female breast cancer 29.6 TP53 PGR MLH1 ESR1 ERBB2 CDKN2A
27 synchronous bilateral breast carcinoma 29.5 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
28 deficiency anemia 29.5 TP53 RAD51 PALB2 BRCA2 BRCA1 ATM
29 lobular neoplasia 29.5 TP53 PGR PALB2 ESR1 ERBB2 CDH1
30 papillary serous adenocarcinoma 29.5 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
31 breast fibroadenoma 29.4 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
32 adenocarcinoma 29.4 TP53 MLH1 ERBB2 CDKN2A CDH1 BRCA2
33 squamous cell carcinoma 29.3 TP53 GSTP1 FHIT ERBB2 CHEK2 CDKN2A
34 breast ductal carcinoma 29.3 TP53 PGR ESR1 ERBB2 CDH1 BRCA2
35 cowden syndrome 1 29.3 TP53 PALB2 MLH1 CHEK2 BRCA2 BRCA1
36 adenoid cystic carcinoma 29.2 TP53 PGR ERBB2 CHEK2 CDKN2A CDH1
37 inherited cancer-predisposing syndrome 28.9 TP53 RAD51D RAD51C PALB2 MLH1 CHEK2
38 bap1 tumor predisposition syndrome 28.9 TP53 RAD51D RAD51C PALB2 MLH1 CHEK2
39 wilms tumor 1 28.7 TP53 PGR PALB2 ESR1 ERBB2 CHEK2
40 gastric cancer 28.7 TP53 MLH1 GSTP1 FHIT ESR1 ERBB2
41 esophageal cancer 28.6 TP53 MLH1 GSTP1 FHIT ESR1 ERBB2
42 serous cystadenocarcinoma 28.3 TP53 RAD51D RAD51C PGR MLH1 ESR1
43 endometrial cancer 28.1 TP53 RAD51 PGR MLH1 GSTP1 FHIT
44 hereditary breast ovarian cancer syndrome 28.1 TP53 RAD51D RAD51C RAD51 PGR PALB2
45 aplastic anemia 28.1 TP53 RAD51D RAD51C RAD51 PALB2 MLH1
46 diffuse gastric and lobular breast cancer syndrome 28.0 TP53 RAD51D RAD51C PALB2 MLH1 ERBB2
47 sporadic breast cancer 27.9 TP53 RAD51C RAD51 PGR PALB2 FHIT
48 breast cancer 27.9 TP53 RAD51D RAD51C RAD51 PGR PALB2
49 li-fraumeni syndrome 27.9 TP53 RAD51D RAD51C RAD51 PALB2 MLH1
50 lung cancer 27.9 TP53 RAD51 PALB2 MLH1 GSTP1 FHIT

Graphical network of the top 20 diseases related to Bilateral Breast Cancer:



Diseases related to Bilateral Breast Cancer

Symptoms & Phenotypes for Bilateral Breast Cancer

GenomeRNAi Phenotypes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

25 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.65 BARD1 BRCA1 BRCA2 CDKN2A MLH1 PALB2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.65 ATM BRCA1 BRCA2 CDKN2A MLH1 PALB2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.65 ATM BARD1 BRCA1 BRCA2 CHEK2 MLH1
4 Decreased viability GR00221-A-1 10.61 CDKN2A ESR1
5 Decreased viability GR00221-A-2 10.61 CHEK2 ESR1 BRCA1
6 Decreased viability GR00221-A-3 10.61 ATM CDKN2A CHEK2 ERBB2 BRCA1
7 Decreased viability GR00221-A-4 10.61 ATM CDKN2A CHEK2 ERBB2 ESR1
8 Decreased viability GR00301-A 10.61 BRCA1
9 Decreased viability GR00342-S-2 10.61 CHEK2
10 Decreased viability GR00386-A-1 10.61 ESR1
11 Decreased viability GR00402-S-2 10.61 ESR1
12 Decreased homologous recombination repair frequency GR00151-A-1 10.46 BARD1 BRCA1 RAD51
13 Decreased homologous recombination repair frequency GR00151-A-2 10.46 BRCA1 RAD51
14 Decreased homologous recombination repair frequency GR00236-A-1 10.46 BARD1 BRCA1 BRCA2 PALB2 RAD51
15 Decreased homologous recombination repair frequency GR00236-A-2 10.46 BARD1 BRCA1 BRCA2 PALB2 RAD51
16 Decreased homologous recombination repair frequency GR00236-A-3 10.46 BARD1 BRCA1 BRCA2 PALB2 RAD51
17 no effect GR00402-S-1 10.17 ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
18 no effect GR00402-S-2 10.17 ATM BARD1 BRCA1 BRCA2 CDH13 CDKN2A
19 Increased ionizing radiation sensitivity GR00232-A-1 9.95 ATM BARD1 BRCA1 BRCA2 CDH1 GSTP1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-1 9.86 CHEK2 MLH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.86 GSTP1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.86 GSTP1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.86 CHEK2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.86 CHEK2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.86 CHEK2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.86 CHEK2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.86 MLH1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.86 GSTP1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-142 9.86 CHEK2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.86 MLH1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-200 9.86 MLH1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.86 CHEK2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.86 MLH1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.86 CHEK2
35 Synthetic lethal with cisplatin GR00101-A-1 9.81 BARD1 BRCA1 BRCA2 RAD51
36 Decreased viability with cisplatin GR00101-A-4 9.8 BARD1 BRCA1 BRCA2 RAD51
37 Increased homologous recombination repair frequency GR00236-A-1 9.56 PGR
38 Increased homologous recombination repair frequency GR00236-A-2 9.56 PGR
39 Decreased viability after ionizing radiation GR00232-A-2 9.54 ATM BRCA1 BRCA2
40 Decreased viability in pancreas lineage GR00235-A 9.5 CHEK2 PGR TP53
41 Increased cell death in HCT116 cells GR00103-A-0 9.18 RAD51

MGI Mouse Phenotypes related to Bilateral Breast Cancer:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.48 ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
2 homeostasis/metabolism MP:0005376 10.42 ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
3 growth/size/body region MP:0005378 10.38 ATM BARD1 BRCA1 BRCA2 CDH1 CDKN2A
4 endocrine/exocrine gland MP:0005379 10.33 ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
5 embryo MP:0005380 10.31 ATM BARD1 BRCA1 BRCA2 CDH1 CDKN2A
6 nervous system MP:0003631 10.3 ATM BARD1 BRCA1 BRCA2 CDKN2A CHEK2
7 cellular MP:0005384 10.24 ATM BARD1 BRCA1 BRCA2 CDH1 CDKN2A
8 normal MP:0002873 10.19 BARD1 BRCA1 BRCA2 CDH1 ERBB2 ESR1
9 limbs/digits/tail MP:0005371 10.16 BRCA1 BRCA2 ERBB2 ESR1 HIC1 PALB2
10 digestive/alimentary MP:0005381 10.1 BRCA1 BRCA2 CDH1 CDKN2A ERBB2 ESR1
11 cardiovascular system MP:0005385 10.1 ATM BRCA1 CDH1 CDH13 CDKN2A CHEK2
12 immune system MP:0005387 10.03 ATM BRCA1 BRCA2 CDH1 CDKN2A CHEK2
13 reproductive system MP:0005389 10.03 ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
14 mortality/aging MP:0010768 9.93 ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
15 integument MP:0010771 9.5 ATM BRCA1 BRCA2 CDH1 CDH13 CDKN2A

Drugs & Therapeutics for Bilateral Breast Cancer

Drugs for Bilateral Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adenosine Approved, Investigational Phase 3 58-61-7 60961
2
Tucatinib Approved, Investigational Phase 3 937263-43-9 51039094
3
Trastuzumab Approved, Investigational Phase 3 180288-69-1
4
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
5
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
6
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
7
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
8
Tamoxifen Approved Phase 3 10540-29-1, 54965-24-1 2733526
9
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
10
Ado-Trastuzumab Emtansine Phase 3
11 Antineoplastic Agents, Immunological Phase 3
12
Maytansine Phase 3
13 Protein Kinase Inhibitors Phase 3
14 Estrogens Phase 3
15 Antineoplastic Agents, Hormonal Phase 3
16 Estrogen Receptor Modulators Phase 3
17 Estrogen Receptor Antagonists Phase 3
18 Estrogen Antagonists Phase 3
19 Hormones Phase 3
20 Hormone Antagonists Phase 3
21 Aromatase Inhibitors Phase 3
22 Citrate Phase 3
23 Selective Estrogen Receptor Modulators Phase 3
24
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
25
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
26
Sargramostim Approved, Investigational Phase 2 123774-72-1
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28
Molgramostim Investigational Phase 2 99283-10-0
29 Folate Phase 2
30 Alkylating Agents Phase 2
31 Vaccines Phase 2
32 Antirheumatic Agents Phase 2
33 Vitamin B9 Phase 2
34 Antineoplastic Agents, Alkylating Phase 2
35 Vitamin B Complex Phase 2
36 Immunosuppressive Agents Phase 2
37 Immunologic Factors Phase 2
38 Antimitotic Agents Phase 2
39 Tubulin Modulators Phase 2
40 Epothilones Phase 2
41 Epothilone B Phase 2 4456137
42
Progesterone Approved, Vet_approved Phase 1 57-83-0 5994

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib Recruiting NCT04457596 Phase 3 Placebo Administration;Tucatinib
2 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
3 Volumetric Lumpectomy Specimen Image Visualization for Intraoperatively Directing Cavity Shaves, a Phase II Study (VIVID) Recruiting NCT05545150 Phase 2
4 Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer Active, not recruiting NCT03012100 Phase 2 Cyclophosphamide
5 A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer Active, not recruiting NCT00877500 Phase 2 Ixabepilone
6 A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Recruiting NCT04052555 Phase 1 Berzosertib
7 Genome-Wide Association Study of Radiation Exposure and Bilateral Breast Cancer Active, not recruiting NCT00903591

Search NIH Clinical Center for Bilateral Breast Cancer

Genetic Tests for Bilateral Breast Cancer

Anatomical Context for Bilateral Breast Cancer

Organs/tissues related to Bilateral Breast Cancer:

MalaCards : Breast, Lymph Node, Prostate, Skin, Ovary, Cervix, Bone Marrow

Publications for Bilateral Breast Cancer

Articles related to Bilateral Breast Cancer:

(show top 50) (show all 943)
# Title Authors PMID Year
1
A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family. 53 62
19288190 2010
2
A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer. 53 62
19649703 2010
3
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. 53 62
20104584 2010
4
Robotic resection of intraductal neoplasm of the pancreas. 53 62
19698031 2009
5
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region. 53 62
19393826 2009
6
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. 53 62
19153073 2009
7
Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer. 53 62
19372713 2009
8
Accuracy of the BRCAPRO model among women with bilateral breast cancer. 53 62
19127556 2009
9
Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. 53 62
19629752 2009
10
Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. 53 62
18264724 2008
11
Altered DNA binding by the human Rad51-R150Q mutant found in breast cancer patients. 53 62
17666788 2007
12
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]. 53 62
17557253 2007
13
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. 53 62
16331614 2006
14
Association of common ATM polymorphism with bilateral breast cancer. 53 62
15756685 2005
15
A comparison of bilateral breast cancers in BRCA carriers. 53 62
15941968 2005
16
BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. 53 62
15319244 2004
17
ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. 53 62
14562025 2003
18
Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. 53 62
12673797 2003
19
Sex hormone-binding globulin polymorphisms in familial and sporadic breast cancer. 53 62
12151349 2002
20
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. 53 62
11802208 2002
21
BRCA1 and BRCA2 mutations in Russian familial breast cancer. 53 62
11793480 2002
22
Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. 53 62
11556836 2001
23
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. 53 62
11389159 2001
24
Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. 53 62
11149425 2001
25
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. 53 62
11130383 2000
26
Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. 53 62
10737987 2000
27
Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure. 53 62
10699917 2000
28
Identification of Rad51 alteration in patients with bilateral breast cancer. 53 62
10807537 2000
29
BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. 53 62
10573018 1999
30
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. 53 62
10188893 1999
31
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. 53 62
9333265 1997
32
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. 53 62
9145677 1997
33
Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. 53 62
9157994 1997
34
Germline mutation of BRCA1 in Japanese breast cancer families. 53 62
7627958 1995
35
Estrogen and progesterone receptor content in bilateral breast cancer. 53 62
7651928 1995
36
Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1. 53 62
8281142 1993
37
Bilateral breast cancer: one disease or two? 53 62
1663803 1991
38
Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients. 62
36324133 2022
39
Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003-2017). 62
36166112 2022
40
Concurrent Pathogenic Variants of BRCA1, MUTYH and CHEK2 in a Hereditary Cancer Family. 62
36368126 2022
41
Comparison of 68 Ga-FAPI PET and 18 F-FDG PET Findings in a Patient With Bilateral Breast Cancer of 2 Different Histopathologies. 62
35695729 2022
42
A novel germline mutation of TP53 with breast cancer diagnosed as Li-Fraumeni syndrome. 62
36219266 2022
43
Cystic degeneration during neo-adjuvant chemotherapy predicts squamous metaplasia of triple negative breast cancer: report of two cases. 62
36186230 2022
44
Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort. 62
35668306 2022
45
HBOC syndrome with an uncharacterized variant in the BRCA1 gene in a patient diagnosed with endometrial cancer after surgery for bilateral breast cancer: A case report. 62
35949594 2022
46
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. 62
35442755 2022
47
Management of Crohn's disease relapse during neoadjuvant chemotherapy for bilateral breast cancer: a case report. 62
36176955 2022
48
Is laterality in breast Cancer still worth studying? Local experience in Bahrain. 62
36088284 2022
49
Synchronous bilateral chest wall irradiation with regional nodal irradiation: A literature review of techniques and a case study. 62
35961182 2022
50
Retraction notice to "Bilateral breast cancer resection performed under the bilateral transversus thoracic muscle plane block" [J. Clin. Anesth. 33(2016)413]. 62
35393183 2022

Variations for Bilateral Breast Cancer

ClinVar genetic disease variations for Bilateral Breast Cancer:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BRCA1 NM_007294.4(BRCA1):c.1504_1508del (p.Leu502fs) DEL Pathogenic
37417 rs80357888 GRCh37: 17:41246040-41246044
GRCh38: 17:43094023-43094027
2 BRCA2 NM_000059.4(BRCA2):c.574dup (p.Met192fs) DUP Pathogenic
51926 rs397507802 GRCh37: 13:32900692-32900693
GRCh38: 13:32326555-32326556
3 PALB2 NM_024675.4(PALB2):c.3428T>A (p.Leu1143His) SNV Uncertain Significance
126740 rs62625284 GRCh37: 16:23614913-23614913
GRCh38: 16:23603592-23603592
4 SDHB NM_003000.3(SDHB):c.269G>A (p.Arg90Gln) SNV Uncertain Significance
201609 rs570278423 GRCh37: 1:17359572-17359572
GRCh38: 1:17033077-17033077
5 SMARCA4 NM_003072.5(SMARCA4):c.403C>G (p.Pro135Ala) SNV Uncertain Significance
238447 rs150949949 GRCh37: 19:11096912-11096912
GRCh38: 19:10986236-10986236
6 MSH6 NM_000179.3(MSH6):c.3727A>T (p.Thr1243Ser) SNV Uncertain Significance
127589 rs147453999 GRCh37: 2:48033423-48033423
GRCh38: 2:47806284-47806284
7 ATM NM_000051.4(ATM):c.2021A>G (p.His674Arg) SNV Uncertain Significance
141183 rs201762714 GRCh37: 11:108124663-108124663
GRCh38: 11:108253936-108253936
8 MC1R NM_002386.4(MC1R):c.104G>A (p.Cys35Tyr) SNV Uncertain Significance
430181 rs779504604 GRCh37: 16:89985770-89985770
GRCh38: 16:89919362-89919362

Expression for Bilateral Breast Cancer

Search GEO for disease gene expression data for Bilateral Breast Cancer.

Pathways for Bilateral Breast Cancer

Pathways related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TP53 RAD51D RAD51 PGR MLH1 ESR1
2
Show member pathways
13.85 TP53 RAD51 ESR1 ERBB2 CHEK2 CDKN2A
3
Show member pathways
13.79 TP53 RAD51D RAD51C RAD51 PALB2 MLH1
4
Show member pathways
13.54 TP53 RAD51C RAD51 MLH1 CHEK2 CDKN2A
5
Show member pathways
13.19 TP53 RAD51D RAD51C RAD51 PALB2 MLH1
6
Show member pathways
13 TP53 RAD51D MLH1 CHEK2 CDKN2A BRCA1
7
Show member pathways
12.96 TP53 RAD51 MLH1 CHEK2 BRCA2 BRCA1
8
Show member pathways
12.81 ATM BARD1 BRCA1 CDKN2A CHEK2 TP53
9
Show member pathways
12.77 BRCA2 CDH1 CDKN2A ERBB2 FHIT MLH1
10
Show member pathways
12.76 RAD51C RAD51 MLH1 BRCA2 BRCA1 ATM
11 12.74 TP53 CDKN2A CDH1 BRCA1 BARD1 ATM
12
Show member pathways
12.74 ATM BARD1 BRCA1 BRCA2 MLH1 PALB2
13
Show member pathways
12.67 RAD51C RAD51 PALB2 MLH1 BRCA2 BRCA1
14
Show member pathways
12.66 TP53 RAD51 ESR1 CHEK2 BRCA2 BRCA1
15
Show member pathways
12.45 TP53 ESR1 ERBB2 CDH1
16
Show member pathways
12.44 TP53 RAD51 PGR ESR1 ERBB2 BRCA2
17
Show member pathways
12.43 TP53 ERBB2 CHEK2 ATM
18
Show member pathways
12.43 PGR ESR1 CHEK2 CDKN2A BRCA1
19
Show member pathways
12.42 TP53 CHEK2 BRCA1 BARD1 ATM
20 12.38 TP53 RAD51 MLH1 GSTP1 CHEK2 CDKN2A
21
Show member pathways
12.31 RAD51D RAD51C RAD51 PALB2 BRCA2 BRCA1
22
Show member pathways
12.27 TP53 CHEK2 CDKN2A ATM
23
Show member pathways
12.23 TP53 CHEK2 BRCA1 ATM
24
Show member pathways
12.17 TP53 RAD51 CHEK2 BRCA1 ATM
25 11.9 TP53 ERBB2 ATM
26
Show member pathways
11.87 TP53 RAD51 CHEK2 BRCA1 ATM
27
Show member pathways
11.86 ATM BRCA1 BRCA2 CDKN2A CHEK2 RAD51
28
Show member pathways
11.82 TP53 CHEK2 CDKN2A ATM
29 11.79 TP53 RAD51 ESR1 CHEK2 CDH1 BRCA2
30 11.76 ATM BRCA1 CDKN2A HIC1
31 11.75 TP53 ERBB2 CDKN2A
32 11.73 TP53 ERBB2 BRCA1 ATM
33 11.72 TP53 ESR1 CDKN2A
34 11.69 PGR ESR1 BRCA1
35 11.63 TP53 CHEK2 CDKN2A ATM
36
Show member pathways
11.62 TP53 RAD51 CHEK2 BRCA2 BRCA1 BARD1
37 11.58 TP53 CHEK2 BRCA1 BARD1 ATM
38 11.55 CDKN2A BRCA2 ATM
39
Show member pathways
11.52 CHEK2 GSTP1 MLH1
40
Show member pathways
11.52 ATM CHEK2 TP53
41 11.51 TP53 ERBB2 CDKN2A CDH1
42 11.47 TP53 CHEK2 BRCA1 BARD1 ATM
43 11.46 BRCA2 CDKN2A CHEK2 ESR1
44 11.46 ATM MLH1 PGR RAD51
45 11.37 TP53 CHEK2 ATM
46 11.36 PGR ESR1 ERBB2
47 11.36 TP53 BRCA1 ATM
48 11.34 ATM BARD1 BRCA1 RAD51 TP53
49 11.18 TP53 RAD51 PALB2 MLH1 CHEK2 BRCA2
50
Show member pathways
11.14 TP53 CDKN2A ATM

GO Terms for Bilateral Breast Cancer

Cellular components related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.68 ATM BARD1 BRCA1 BRCA2 CDKN2A CHEK2
2 nucleoplasm GO:0005654 10.57 ATM BARD1 BRCA1 BRCA2 CDKN2A CHEK2
3 microtubule organizing center GO:0005815 9.99 TP53 RAD51D RAD51 BRCA2 ATM
4 chromosome, telomeric region GO:0000781 9.96 ATM BRCA2 CHEK2 RAD51 RAD51D
5 replication fork GO:0005657 9.85 TP53 RAD51D RAD51C
6 BRCA1-C complex GO:0070533 9.84 BRCA1 BARD1
7 condensed nuclear chromosome GO:0000794 9.83 RAD51 MLH1 BRCA1
8 BRCA1-BARD1 complex GO:0031436 9.8 BARD1 BRCA1
9 Rad51B-Rad51C-Rad51D-XRCC2 complex GO:0033063 9.78 RAD51C RAD51D
10 BRCA1-B complex GO:0070532 9.76 BARD1 BRCA1
11 lateral element GO:0000800 9.63 RAD51 BRCA2 BRCA1
12 condensed chromosome GO:0000793 9.62 RAD51 MLH1 BRCA1
13 DNA repair complex GO:1990391 9.56 PALB2 BRCA2 BRCA1 ATM
14 nuclear ubiquitin ligase complex GO:0000152 9.23 RAD51 BRCA2 BRCA1 BARD1

Biological processes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-templated transcription GO:0045893 10.48 TP53 ESR1 CHEK2 CDKN2A CDH1 BRCA2
2 positive regulation of gene expression GO:0010628 10.36 TP53 PGR ERBB2 CDKN2A BRCA1 ATM
3 regulation of cell cycle GO:0051726 10.34 TP53 RAD51D CDKN2A BRCA1 BARD1 ATM
4 double-strand break repair GO:0006302 10.21 TP53 CHEK2 BRCA2 BRCA1 ATM
5 protein autoubiquitination GO:0051865 10.19 RAD51 BRCA2 BRCA1 BARD1
6 cell cycle GO:0007049 10.18 ATM BRCA1 BRCA2 CDKN2A CHEK2 MLH1
7 cellular senescence GO:0090398 10.15 TP53 CDKN2A BRCA2 ATM
8 somitogenesis GO:0001756 10.13 ATM PALB2 TP53
9 cellular response to gamma radiation GO:0071480 10.13 TP53 RAD51 CHEK2 ATM
10 cellular response to ionizing radiation GO:0071479 10.13 TP53 RAD51 BRCA2 BRCA1 BARD1
11 replicative senescence GO:0090399 10.1 TP53 CHEK2 CDKN2A ATM
12 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 10.09 BRCA2 CHEK2 TP53
13 histone H2A monoubiquitination GO:0035518 10.08 BARD1 BRCA1 BRCA2 RAD51
14 response to X-ray GO:0010165 10.06 TP53 RAD51 BRCA2
15 regulation of DNA damage checkpoint GO:2000001 10.06 RAD51 BRCA2 BRCA1 BARD1
16 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 10.04 TP53 CHEK2 ATM
17 signal transduction in response to DNA damage GO:0006975 10.02 CHEK2 ATM
18 signal transduction in response to DNA damage GO:0042770 10.02 CHEK2 ATM
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 10.01 BRCA2 CHEK2 TP53
20 telomere maintenance via recombination GO:0000722 10.01 RAD51D RAD51C RAD51 BRCA2
21 response to gamma radiation GO:0010332 10 TP53 CHEK2 BRCA2
22 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 10 MLH1 HIC1 CHEK2 BRCA2 BRCA1 ATM
23 double-strand break repair via homologous recombination GO:0000724 10 ATM BRCA1 BRCA2 PALB2 RAD51 RAD51C
24 DNA strand resection involved in replication fork processing GO:0110025 9.97 BRCA1 BARD1
25 DNA recombination GO:0006310 9.97 BRCA1 BRCA2 PALB2 RAD51 RAD51C RAD51D
26 reciprocal meiotic recombination GO:0007131 9.97 RAD51D RAD51C RAD51 MLH1 ATM
27 cellular response to indole-3-methanol GO:0071681 9.94 CDH1 BRCA1
28 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.93 TP53 ESR1
29 strand invasion GO:0042148 9.93 RAD51D RAD51
30 chromosome organization GO:0051276 9.91 TP53 RAD51D BRCA2
31 mitotic recombination-dependent replication fork processing GO:1990426 9.9 RAD51 BRCA2
32 chromosome organization involved in meiotic cell cycle GO:0070192 9.83 RAD51 ATM
33 DNA metabolic process GO:0006259 9.83 RAD51D RAD51C RAD51
34 DNA repair GO:0006281 9.83 RAD51D RAD51C RAD51 PALB2 MLH1 CHEK2
35 chordate embryonic development GO:0043009 9.82 BRCA2 BRCA1
36 negative regulation of immature T cell proliferation in thymus GO:0033088 9.82 ERBB2 CDKN2A
37 cellular response to DNA damage stimulus GO:0006974 9.55 TP53 RAD51D RAD51C RAD51 PALB2 MLH1

Molecular functions related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.13 ATM BRCA1 BRCA2 CDKN2A ESR1 HIC1
2 enzyme binding GO:0019899 10.03 TP53 RAD51 PGR MLH1 ESR1 BRCA1
3 nucleotide binding GO:0000166 10.02 RAD51D RAD51C RAD51 MLH1 FHIT ERBB2
4 identical protein binding GO:0042802 10.02 ATM BRCA1 BRCA2 CDH1 CDH13 CHEK2
5 single-stranded DNA binding GO:0003697 9.92 RAD51D RAD51 MLH1 BRCA2
6 ATP-dependent DNA damage sensor activity GO:0140664 9.23 RAD51D RAD51C RAD51 MLH1

Sources for Bilateral Breast Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....